Biological Subtypes and Survival Outcomes in Breast Cancer Patients with Brain Metastases (Study of the Anatolian Society of Medical Oncology)

Basit Öğe Kaydı
dc.authoridYücel, Şebnem/0000-0001-6235-7927
dc.authoridKOÇER, Murat/0000-0002-1541-640X
dc.authoridkoçer, murat/0000-0002-1541-640X
dc.authoridGumusay, Ozge/0000-0002-6236-9829
dc.authoridguven mert, aslihan/0000-0002-1298-3855
dc.authoridElkıran, Emin Tamer/0000-0001-6681-7249
dc.authoridKaplan, Muhammet Ali/0000-0003-0882-0524
dc.authorwosidYücel, Şebnem/AAY-6737-2021
dc.authorwosidGeredeli, Caglayan/AAN-4122-2020
dc.authorwosidDurnalı, Ayşe/ABC-2229-2021
dc.authorwosidKOÇER, Murat/GQH-4487-2022
dc.authorwosidKucukoner, Mehmet/E-1162-2013
dc.authorwosidDemir, Lutfiye/A-6118-2017
dc.authorwosidkoçer, murat/AAD-2345-2019
dc.contributor.authorKaplan, Muhammet Ali
dc.contributor.authorIsikdogan, Abdurrahman
dc.contributor.authorKoca, Dogan
dc.contributor.authorKucukoner, Mehmet
dc.contributor.authorGumusay, Ozge
dc.contributor.authorYildiz, Ramazan
dc.contributor.authorDayan, Adem
dc.date.accessioned2024-08-04T20:36:00Z
dc.date.available2024-08-04T20:36:00Z
dc.date.issued2012
dc.departmentİnönü Üniversitesien_US
dc.description.abstractBackground: The aim of this study is to determine the relationship between the survival outcomes and biological subtype in breast cancer patients with brain metastases. Methods: We retrospectively evaluated clinical data from 422 breast cancer patients with brain metastases between 2001 and 2011 from referral centers in Turkey. The study population was divided into four biological subtypes according to their hormone receptor status and HER2 expression. Results: Systemic treatment prolonged median overall survival (OS) after brain metastases in the entire group (14 vs. 3.2 months, p < 0.001). It also prolonged median OS after brain metastases in the triple negative (7.5 vs. 1.6 months, p = 0.010) and luminal A (14.3 vs. 7.1 months, p = 0.003) subgroups. The median OS for untreated patients, chemotherapy and/or hormonal therapy receiving patients, and chemotherapy and/or hormonal therapy plus targeted therapy receivers was 2, 5.8, and 17.7 months, respectively (p < 0.001), in the HER2-overexpressing subgroup. In the luminal B subgroup, it was 3.7, 5.3, and 15.4 months, respectively (p = 0.003). Conclusions: The use of systemic therapy improves OS after brain metastases in all biological subgroups. Targeted therapies also improve OS after brain metastases in HER2-positive patients. The combined use of targeted therapies and lapatinib are superior to single use and trastuzumab, respectively, in these patients. Copyright (C) 2012 S. Karger AG, Baselen_US
dc.identifier.doi10.1159/000338782
dc.identifier.endpage150en_US
dc.identifier.issn0030-2414
dc.identifier.issn1423-0232
dc.identifier.issue3en_US
dc.identifier.pmid22814315en_US
dc.identifier.scopus2-s2.0-84863858493en_US
dc.identifier.scopusqualityQ2en_US
dc.identifier.startpage141en_US
dc.identifier.urihttps://doi.org/10.1159/000338782
dc.identifier.urihttps://hdl.handle.net/11616/95721
dc.identifier.volume83en_US
dc.identifier.wosWOS:000307877100004en_US
dc.identifier.wosqualityQ3en_US
dc.indekslendigikaynakWeb of Scienceen_US
dc.indekslendigikaynakScopusen_US
dc.indekslendigikaynakPubMeden_US
dc.language.isoenen_US
dc.publisherKargeren_US
dc.relation.ispartofOncologyen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/closedAccessen_US
dc.subjectBreast canceren_US
dc.subjectBrain metastasisen_US
dc.subjectBiological subtypeen_US
dc.titleBiological Subtypes and Survival Outcomes in Breast Cancer Patients with Brain Metastases (Study of the Anatolian Society of Medical Oncology)en_US
dc.typeArticleen_US

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayın Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu